— Know what they know.
Not Investment Advice

NRSN

NeuroSense Therapeutics Ltd.
1W: -12.4% 1M: -14.5% 3M: -9.3% YTD: -3.5% 1Y: -29.6% 3Y: -57.9%
$0.75
-0.04 (-4.53%)
After Hours: $0.80 (+0.05, +6.21%)
NASDAQ · Healthcare · Biotechnology · $18.6M · Alpha Radar Sell · Power 29
Smart Money Score
Watch 25
Insider
Congress
ETF Holdings
Key Statistics
Market Cap$18.6M
52W Range0.68-2.6
Volume110,876
Avg Volume234,520
Beta1.61
Dividend
Analyst Ratings
1 Buy 1 Hold 0 Sell
Consensus Buy
Company Info
CEOAlon Ben-Noon
Employees17
SectorHealthcare
IndustryBiotechnology
IPO Date2021-12-09
Building B
Herzliya 4672562
IL
972 9 799 6183
About NeuroSense Therapeutics Ltd.

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

Recent Insider Trades

No insider trades found

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms